Discuss Survodutide on glp1chat
Join the forum to discuss research with other members.
At a glance
Survodutide activates GLP-1 and glucagon receptors. Clinical studies track how the two signals affect appetite, body weight and liver-related measures over time.
GLP-1 signaling can help reduce appetite, while glucagon signaling has additional effects on fuel use and the liver. Survodutide combines both in one molecule. Trials therefore track weight as well as liver-related measures and unwanted effects over time. Two drugs can share these receptor labels yet behave differently, so results for another dual agonist are not automatically Survodutide results.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited studies address weight and liver-related outcomes. Their results require the original population, treatment period and adverse-event context.[1][2][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Survodutide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Titration (2 mL = 5 mg/mL)
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing)[1][2]. *Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support metabolic improvement and weight management through dual GLP‑1/glucagon receptor activation[1][3].
- Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).
- Dose Range: 0.6–6.0 mg weekly with gradual titration over 10–12 weeks.
- Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.
Suggested weekly titration approach based on clinical trial designs[1][2].
- Start: 0.6 mg weekly; increase by 0.6 mg every 2 weeks as tolerated.
- Target: 4.8–6.0 mg weekly by weeks 11–13.
- Frequency: Once per week (subcutaneous).
- Cycle Length: 12–16 weeks minimum; phase 3 trials extend to 48–72 weeks.
- Timing: Same day each week; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at ≤−20 °C (≤−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light and avoid repeated freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week weekly protocol with gradual titration.
-
Peptide Vials (Survodutide, 10 mg each):
- 8 weeks ≈ 2 vials (~17 mg total)
- 12 weeks ≈ 4 vials (~39 mg total)
- 16 weeks ≈ 7 vials (~63 mg total)
-
Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:
- Per week: 1 syringe (once weekly)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Obesity (Silver Spring) (2024) — Wharton et al. SYNCHRONIZE‑1 & 2 phase 3 trial design for survodutide in obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
- 07
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
MedlinePlus (NIH) — Giving an insulin injection: patient guide for subcutaneous technique (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Public health resource
Veterans Affairs (2023) — Insulin injection: how to use and where to inject (injection sites, rotation guidance) (opens in a new tab)www.veteranshealthlibrary.va.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.